Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience

Lebovic, Daniel; Zhang, Ling; Alsina, Melissa; Nishihori, Taiga; Shain, Kenneth H.; Sullivan, Daniel M.; Ochoa-Bayona, José L.; Kharfan‐Dabaja, Mohamed A.; Baz, Rachid

doi:10.1016/j.clml.2011.06.010

Cited by 37 publications

(34 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…61 A single-center retrospective analysis of all pPCL and sPCL patients has shown a survival advantage for bortezomib-treated patients compared with a non-bortezomib-treated group. 75 This is in line with a retrospective analysis of 73 pPCL patients treated with different regimens, which showed best results for patients treated with bortezomib followed by autologous SCT (auto-SCT). 51 In contrast, a retrospective analysis performed by the Intergroupe Francophone du Myélome showed no improvement in OS for patients treated with relatively short courses of bortezomib.…”

Section: Bortezomibsupporting

confidence: 50%

“…Available data suggest that bortezomib-based treatment is the most effective treatment modality in sPCL. 61,68,73,75 In case of refractory disease, combination approaches, such as lenalidomide combined with bortezomib, 97 or participation in a clinical trial, if feasible, can be considered. High-dose methylprednisolone may be a useful adjunct together with other chemotherapeutics and novel agents.…”

Section: Treatment Recommendations For Spclmentioning

confidence: 99%

See 1 more Smart Citation

How I treat plasma cell leukemia

Donk

Lokhorst

Anderson

et al. 2012

Blood

115

106

View full text Add to dashboard Cite

Section: Bortezomibsupporting

confidence: 50%

Section: Treatment Recommendations For Spclmentioning

confidence: 99%

How I treat plasma cell leukemia

Donk

Lokhorst

Anderson

et al. 2012

Blood

115

106

View full text Add to dashboard Cite

“…To our knowledge, novel agents and auto-HSCT as consolidation after induction therapy are useful for the treatment of pPCL patients as well as in improving their outcome [13,15,16,17,18,19,20,21]. Recently, Musto et al [22] conducted a first prospective trial of lenalidomide and dexamethasone therapy in a series of previously untreated pPCL patients, and they indicated that the median OS was 28 months after a median follow-up of 34 months.…”

Section: Discussionmentioning

confidence: 99%

Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma

Iriuchishima

Ozaki²,

Konishi³

et al. 2015

Acta Haematol

View full text Add to dashboard Cite

We investigated the treatment and outcome of Japanese patients with primary plasma cell leukemia (pPCL) in the era of novel agents and analyzed the risk factors affecting survival. Among 3,318 patients with symptomatic multiple myeloma (MM), 38 patients were diagnosed with pPCL. The median overall survival (OS) of the pPCL patients was 2.85 years, which was significantly extended compared with that in previous reports. The proportion of patients treated with novel agents was 61%. The OS of the patients treated with novel agents was significantly extended compared with that of patients treated without novel agents according to the generalized Wilcoxon test (2.85 vs. 1.16 years, p = 0.049). This statistical finding suggests that treatment with novel agents could have prevented early death in the patients with pPCL. Age was the only statistically significant prognostic factor associated with an inferior OS (hazard ratio 4.57). Five patients received maintenance therapy with novel agents, and their OS tended to be longer than that of the other patients without maintenance (4.45 vs. 2.85 years). Unlike MM, OS for pPCL has not been improved significantly over the last decade, especially in elderly patients. Therefore, it is important to establish the treatment strategy, particularly after induction treatment.

show abstract

“…1,[10][11][12][13] However, recent retrospective studies suggest that the incorporation of novel agents as well as ASCT in treating pPCL has improved the median OS to more than 24 months. [14][15][16][17][18][19] Given the lack of large, prospective studies evaluating the survival outcomes in pPCL because of its rarity, we used the Surveillance Epidemiology and End Results (SEER) program to evaluate the survival trends in pPCL patients in the US population during various time intervals based on the availability of ASCT and novel agent therapy.…”

Section: Introductionmentioning

confidence: 99%